Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2017 -- Portola Pharmaceuticals, Inc.^® (NASDAQ:PTLA) announced today that on September 27, 2017, the Compensation Committee of the Board of Directors approved, effective as of September 29, 2017, the grant of inducement stock options to purchase an aggregate of 82,000 shares of common stock to three new employees.

Each stock option shall have an exercise price per share of $54.03, the closing price per share of the Company’s Common Stock on September 29, 2017, and will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares vest ratably over the subsequent 36 months, subject to each new employee's continued service with the Company. Each stock option has a ten-year term and is subject to the terms and conditions of the Company's Inducement Plan and the stock option agreement pursuant to which the option was granted.

The stock options were granted as inducements material to the new employees entering into employment with Portola in accordance with NASDAQ Listing Rule 5635(c)(4).

About Portola Pharmaceuticals, Inc.    
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing its three wholly-owned programs using novel biomarker and genetic approaches that may increase the likelihood of clinical, regulatory and commercial success of its potentially life-saving therapies. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions.

Investor Contact:
Michele Mantynen
Portola Pharmaceuticals
[email protected]

Media Contact:
Patrick Ryan
W2O Group
[email protected]